Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives.

Ioanna A Anastasiou, Dimitris Kounatidis, Natalia G Vallianou, Eleni Rebelos, Irene Karampela, Maria Dalamaga

Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece. · pubmed

Paper

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the expansion of hematopoietic stem cells harboring leukemogenic mutations in the absence of overt malignancy. Strongly associated with advancing age, CHIP is detected by next-generation sequencing of peripheral blood in more than 20% of individuals over 80, most commonly through mutations in

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper discusses the relationship between clonal hematopoiesis of indeterminate potential (CHIP) and cardiometabolic disease, highlighting potential mechanisms linking aging and disease. The relevance stems from its focus on understanding the underlying biological processes associated with aging and their implications for age-related diseases.

Author of this paper? Send a correction.